Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diaphragmatic Effects of Combined Infraclavicular Brachial Plexus Block and Suprascapular Nerve Block (ICB-SNB)

5 de junio de 2026 actualizado por: Ceren Gul AKPINAR, Gazi University

Evaluation of the Effects of Combined Infraclavicular Brachial Plexus Block and Suprascapular Nerve Block on the Diaphragm in Arthroscopic Shoulder Surgery

This prospective observational study was conducted to evaluate the effects of a combined infraclavicular brachial plexus block and anterior suprascapular nerve block on diaphragmatic function in patients undergoing arthroscopic shoulder surgery. A total of 61 adult patients were enrolled in the study. Diaphragmatic excursion was assessed using ultrasonography both prior to block administration and 30 minutes following the procedure during normal and deep breathing. The primary objective was to assess changes in diaphragmatic excursion and determine the incidence of hemidiaphragmatic paralysis associated with this combined block technique. Secondary outcomes included block performance time, duration of postoperative analgesia, the need for additional intraoperative sedation or analgesia, the occurrence of adverse events, and levels of patient and surgeon satisfaction. The study sought to determine whether this regional anesthesia approach could provide effective anesthesia and analgesia while minimizing impairment of diaphragmatic function.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

This prospective observational study was conducted to evaluate the effects of combined infraclavicular brachial plexus block and anterior suprascapular nerve block on diaphragmatic excursion in patients undergoing elective arthroscopic shoulder surgery.

Patients scheduled for arthroscopic shoulder surgery under regional anesthesia were enrolled in the study. Prior to block administration, baseline diaphragmatic excursion was assessed using ultrasonography during both normal and deep breathing. Each measurement was repeated three times, and the mean value was recorded. The same measurements were repeated 30 minutes after completion of the block procedures using an identical protocol.

The percentage change in diaphragmatic excursion between baseline and post-block measurements was calculated for both normal and deep breathing. Hemidiaphragmatic paralysis was categorized according to the degree of reduction in diaphragmatic excursion as absent (≤25% reduction), partial (25.1-74.9% reduction), or complete (≥75% reduction).

All nerve blocks were performed under ultrasound guidance by anesthesiologists experienced in regional anesthesia techniques. The infraclavicular brachial plexus block was performed using 15 mL of 0.5% bupivacaine deposited around the posterior cord and 8 mL of 0.5% bupivacaine around the lateral cord. The anterior suprascapular nerve block was performed with 7 mL of 0.5% bupivacaine. In addition, arthroscopic portal sites were infiltrated with 10 mL of 0.2% bupivacaine to provide supplementary analgesia.

All patients received intravenous midazolam (2 mg) and paracetamol (1 g) during the intraoperative period. Additional analgesic or sedative medication was administered when required according to clinical conditions and surgical needs. Block performance time, requirement for supplemental analgesia or sedation, and any block-related adverse events were recorded.

The primary outcome measure was the change in diaphragmatic excursion measured by ultrasonography 30 minutes after block administration. Secondary outcome measures included the incidence and severity of hemidiaphragmatic paralysis, block performance time, duration of postoperative analgesia, need for additional intraoperative analgesia or sedation, time to first analgesic requirement, patient and surgeon satisfaction, block-related complications, and conversion to general anesthesia.

The study was designed to investigate whether the combination of infraclavicular brachial plexus block and anterior suprascapular nerve block could provide effective anesthesia and analgesia for arthroscopic shoulder surgery while minimizing impairment of diaphragmatic function and reducing the incidence of clinically significant hemidiaphragmatic paralysis.

Tipo de estudio

De observación

Inscripción (Actual)

61

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Ankara
      • Ankara, Ankara, Turquía (Türkiye), 06500
        • Gazi University Faculty of Medicine Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Adult patients aged 18-80 years with ASA physical status I-III undergoing elective arthroscopic shoulder surgery at Gazi University Faculty of Medicine Hospital. Eligible participants received ultrasound-guided combined infraclavicular brachial plexus block and anterior suprascapular nerve block. The study evaluated changes in diaphragmatic excursion measured by ultrasonography before and after block administration.

Descripción

Inclusion Criteria:

  • Patients aged 18-80 years.
  • ASA physical status I-III.
  • Scheduled for elective arthroscopic shoulder surgery.
  • Ability to provide written informed consent

Exclusion Criteria:

  • Refusal to undergo peripheral nerve block.
  • Pre-existing peripheral neuropathy.
  • Known pulmonary, hepatic, or renal disease.
  • Allergy to local anesthetics.
  • Infection at the block site.
  • Pre-existing neurological deficit.
  • Body mass index (BMI) > 40 kg/m².
  • Coagulopathy.
  • Sepsis.
  • Previous surgery at the planned block site.

    • Major psychiatric disorders.
    • Inability to complete diaphragmatic ultrasonographic assessment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Patients Undergoing Arthroscopic Shoulder Surgery
Patients undergoing arthroscopic shoulder surgery who received a combined infraclavicular brachial plexus block and anterior suprascapular nerve block. Diaphragmatic excursion was evaluated using ultrasonography before and after block administration.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Diaphragmatic Excursion at 30 Minutes After Block Administration
Periodo de tiempo: 30 minutes after block administration
Diaphragmatic excursion measured by ultrasonography during normal and deep breathing before block administration and 30 minutes after block administration. The percentage change from baseline was calculated.
30 minutes after block administration

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Hemidiaphragmatic Paralysis
Periodo de tiempo: 30 minutes after block administration
Presence of hemidiaphragmatic paralysis determined by ultrasonographic assessment of diaphragmatic excursion.
30 minutes after block administration
Degree of Hemidiaphragmatic Paralysis
Periodo de tiempo: 30 minutes after block administration
Hemidiaphragmatic paralysis classified as absent (≤25% reduction), partial (25.1-74.9% reduction), or complete (≥75% reduction)
30 minutes after block administration
Block Performance Time
Periodo de tiempo: From needle insertion to completion of the block procedure
Time required to complete the combined infraclavicular brachial plexus block and anterior suprascapular nerve block.
From needle insertion to completion of the block procedure
Additional Intraoperative Analgesia Requirement
Periodo de tiempo: From surgical incision to the end of surgery
Requirement for supplemental analgesic medication during surgery.
From surgical incision to the end of surgery
Time to First Analgesic Requirement
Periodo de tiempo: Up to 24 hours after surgery
Time from completion of the block procedure to the first postoperative analgesic request.
Up to 24 hours after surgery
Block-Related Complications
Periodo de tiempo: From block administration until 24 hours after surgery
Incidence of block-related adverse events including Horner syndrome, hoarseness, nausea/vomiting, and hemodynamic complications.
From block administration until 24 hours after surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: IRFAN GUNGOR, MD, Gazi University Faculty of Medicine

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de febrero de 2025

Finalización primaria (Actual)

20 de julio de 2025

Finalización del estudio (Actual)

20 de julio de 2025

Fechas de registro del estudio

Enviado por primera vez

31 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

5 de junio de 2026

Publicado por primera vez (Actual)

10 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2024-GUTF-028

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data collected during the study will not be shared with other researchers because of institutional policies, ethical considerations, and protection of participant confidentiality.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .